ALFA-D-MANNOSE 1-PHOSPHATE DIPOTASSIUM for PMM2-CDG (Phosphomannomutase 2 congenital disorder of glycosylation)

Inclusion criteria

• {"criterion_text":"- Is willing and able to provide informed consent/assent, directly or through a legally authorized representative\n- Has successfully completed the Treatment Period with GLM101 in a previous clinical study.\n- At least 2 years of age inclusive, at the time of signing the informed consent form (ICF).\n- Molecularly confirmed diagnosis of PMM2-CDG. Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of bi-allelic variants AND phosphomannomutase-2 (PMM2) enzyme activity consistent with a diagnosis of PMM2-CDG. Historical diagnosis including from a prior parent trial is permitted;\n- Male or female participant has appropriate measures in place to prevent pregnancy: if the participant is a female of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile (permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy)) or becomes of childbearing potential during the study, she must not be pregnant (confirmed by a negative serum pregnancy test), is using a medically accepted method of contraception (abstinence, a hormonal contraceptive associated with inhibition of ovulation in conjunction with a barrier method, or use of an intrauterine device), and must agree to continue using this method for 50 days after the last infusion of GLM101. Note: True abstinence: defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (such as calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n- Male or female participant has appropriate measures in place to prevent pregnancy: if the participant is a female of non-childbearing potential, she must be pre-pubertal, surgically sterile, or must have an ovarian dysfunction confirmed by a follicle stimulating hormone (FSH) >40 IU/L and absence of menses for 12 months without an alternative medical cause.\n- Male or female participant has appropriate measures in place to prevent pregnancy: if the participant is a sexually active (or becomes sexually active during the study) male with female partners, the sexually mature, nonsterile male participant agrees to use a medically acceptable method of contraception (abstinence, the partner taking a hormonal contraceptive in conjunction with a male condom, or use by the partner of an intrauterine device with a male condom) and agrees to continue using this method for 50 days after the last infusion of GLM101. Males are considered surgically sterile if they have undergone bilateral orchiectomy or vasectomy at least 3 months prior to Screening.\n- If the participant is male, he must agree to refrain from donating sperm during the study and 50 days after the last infusion of GLM101\n- Is willing and able to comply with this protocol."}

Exclusion criteria

• {"criterion_text":"- Has any other condition that would, in the opinion of the Investigator, potentially compromise the safety or compliance of the participant or preclude the participant’s successful completion of the study\n- Participant is unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, other study procedures, and study restrictions.\n- If female, and breastfeeding\n- Is currently participating in another interventional clinical study or has completed another clinical study with an investigational drug or device (other than GLM101) within 30 days or 5 half-lives before GLM101 infusion\n- Must not have a hypersentivity to GLM101 or anti-histamine pre-medication.\n- Has a history of a severe allergic reaction to any drug or excipients of GLM101 (as listed in the GLM101 IB);\n- Diagnosis of congenital disorder of glycosylation (CDG) other than PMM2; Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of bi-allelic variants AND the defined CDG enzyme activity consistent with a diagnosis of the CDG other than PMM2 CDG\n- If not enrolling directly from a parent study (i.e., more than 28 days from Final Treatment visit in a parent study to date of consent), has an active infection requiring parenteral antibiotics, antivirals, or antifungals or treatment with systemic steroids within 7 days prior to Screening;\n- ALT or AST >3× ULN OR total bilirubin >2× ULN or INR >1.5 (if no anti-coagulation treatment) or INR > 4 (if participant on anti-coagulation treatment) considered clinically significant;\n- Has a history of liver transplant\n- Persons who have been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities;\n- Has a history of drug or alcohol use disorder within the 12 months prior to Screening\n- If not enrolling directly from a parent study (i.e., if more than 28 days from Final Treatment visit in a parent study to date of consent), has had a major surgical procedure within 30 days prior to Screening\n- Has laboratory value(s) outside the laboratory reference range considered clinically significant and not related to PMM2-CDG\n- If female, has a positive serum pregnancy test during Screening.\n- If not enrolling directly from a parent study (i.e., if more than 28 days from Final Treatment visit in a parent study to date of consent), has serology positive for hepatitis B surface antigen or hepatitis C antibody during Screening;\n- Has a QTc ≥ 450 ms, or other clinically significant ECG abnormalities;\n- Has uncontrolled cardiovascular, hepatic, pulmonary, gastro-intestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric or other significant disease;\n- Weight exceeds 120 kg."}

Primary endpoints

• {"endpoint_text":"- Collection of the safety information from the collection of Side effects (or Adverse Events), deaths, and stopping the study due to side effects; Tests from blood and urine (hematology, chemistry, and urinalysis) (compared to before treatment with GLM101); ECG (heart tracings), vital signs (blood pressure, heart rate, and body temperature), and physical exam changes (compared to before treatment with GLM101)","definition_or_measurement_approach":"Safety information collected via adverse event reporting (side effects), deaths, and study discontinuations due to side effects; laboratory tests (blood and urine: hematology, chemistry, urinalysis) compared to pre-treatment baseline; ECGs, vital signs (blood pressure, heart rate, body temperature) and physical exam changes compared to pre-treatment baseline."}

Secondary endpoints

• {"endpoint_text":"- Changes in International Co-operative Ataxia Rating Scale, ICARS (evaluated every 3-6 months, compared to before treatment with GLM101)","definition_or_measurement_approach":"ICARS score changes assessed every 3–6 months versus pre-treatment baseline."}
• {"endpoint_text":"- The amount of Mannose-1-Phosphate (the sugar contained in a lipid bubble, which together make up GLM101) in blood (evaluated at Month 6)","definition_or_measurement_approach":"Measurement of blood Mannose-1-Phosphate concentration assessed at Month 6."}

Spain

Earliest CTIS Part Ii Submission Date

30-05-2024

Latest Decision Or Authorization Date

11-03-2026

Processing Time Days

650

Number Of Sites

1

Number Of Participants

39

Portugal

Earliest CTIS Part Ii Submission Date

04-05-2026

Latest Decision Or Authorization Date

12-05-2026

Processing Time Days

8

Number Of Sites

1

Number Of Participants

5

Primary sponsor

Full Name

Glycomine Inc.

Organisation Type

Pharmaceutical company

Country Of Registered Address

United States

Contract research organisations

Name

Fisher Clinical Services GmbH

Responsibilities

Code 14

Name

Pentara Corp.

Responsibilities

Code 10

Name

MEDPACE LABORATORIES

Responsibilities

Code 4

Name

Medpace Finland Oy

Responsibilities

Codes 1,12,13,3,5,6,8,9

Third parties

• {"country":"Germany","full_name":"Fisher Clinical Services GmbH","duties_or_roles":"Code 14","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Pentara Corp.","duties_or_roles":"Code 10","organisation_type":"Pharmaceutical company"}
• {"country":"Belgium","full_name":"MEDPACE LABORATORIES","duties_or_roles":"Code 4","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"Finland","full_name":"Medpace Finland Oy","duties_or_roles":"Codes 1,12,13,3,5,6,8,9","organisation_type":"Pharmaceutical company"}